IFNA1 and Huntington disease: With regards to cellular immunity, some studies reported a lower IFN-ɣ production three weeks after the second vaccine dose in naïve HD patients compared to HV, as only 71% of HD patients responded to SARS-CoV-2-specific in vitro T cell activation by interferon-ɣ release assay (IGRA) (18).